Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department plans to (a) alter and (b) mitigate the National Institute for Care and Excellence's downgrading of terminal cancer to moderately severe.

The National Institute for Health and Care Excellence (NICE) has not classified terminal cancer as moderately severe. The NICE is an independent body and is responsible for developing the methods and processes it uses to evaluate whether new medicines should be recommended for routine National Health Service funding.

In developing recommendations on whether medicines represent a clinically and cost effective use of NHS resources, NICE is able to apply a weighting that recognises the additional value that society places on treatments for severe conditions. The weighting that is applied is calculated for each appraisal based on information on the expected shortfall in life expectancy and quality of life of people with the condition taking into account existing treatment options. NICE has concluded for several appraisals of medicines for advanced cancer that a weighting should be applied based on the severity of the condition. The latest data for appraisals published up to September 2025, show that NICE has recommended 84.8% of treatments for advanced cancers since the severity modifier was introduced compared to 69.1% under its previous methods.

NICE is monitoring the impact of the changes made following the methods review and has committed to considering modular updates to its methods and processes in the future. NICE has also commissioned research to gather further evidence on societal preferences that will inform future methods reviews.